J&J Seeks Approval For Doxil Plus Velcade In Multiple Myeloma
Supplemental claim for liposomal doxorubicin has a May 21 priority review date, J&J’s Ortho Biotech unit tells “The Pink Sheet” DAILY.
Supplemental claim for liposomal doxorubicin has a May 21 priority review date, J&J’s Ortho Biotech unit tells “The Pink Sheet” DAILY.